Cemiplimab for advanced NUT carcinoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called cemiplimab for people with NUT carcinoma that has spread or cannot be removed. The drug aims to shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with NUT carcinoma.
- You have not received treatment with a PD-1 or PD-L1 inhibitor before.
- You have not had cancer therapy within the last 2 weeks.
- Your overall health is reasonably good (able to care for yourself).
- If you have had brain metastases, they are under control or do not require immediate treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
This trial tests a combination of two new drugs, BND-22 and cemiplimab, for people with certain advanced solid tumors like lung, colorectal, or ovarian cancer. It aims to see if this treatment helps control the cancer and looks at specific markers in your blood and tissue.
This trial tests whether the immunotherapy drug cemiplimab can treat advanced squamous cell skin cancer in people who have had a kidney transplant. It aims to see if the drug can shrink tumors while keeping the transplanted kidney working well.
This Phase 1 trial tests the drug cemiplimab given before and after surgery to reduce the chance that high-risk cutaneous squamous cell cancer comes back. You may be a candidate if your cancer is high-risk on pathology or imaging and is planned for surgical removal.
Hear when a new Metastatic NUT Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.